Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

Inclusion Criteria: * Receiving dialysis for at least 6 months (3 times weekly) before screening * Age: \>=18 * Clinically stable, i.e. hemoglobin within the established range (10.0 to 13.0 g/dl) for at least 12 weeks before screening * Stable intravenous dosage of ERYPO® three times weekly for at least 8 weeks before screening and during screening with a maximal weekly dosage of 300 IU/kg body weight (stable is defined as \<25% change (up or down) in weekly dose and no change in frequency over 8 weeks prior screening and 10 weeks prior randomisation) * Baseline hemoglobin concentration of 10.0 to 13.0 g/dl (mean of two pre-randomization pre-dialysis samples of Hb at visit -2 and visit 1) * Serum ferritin \>=100 µg/l and/or saturated transferrin levels \>=20% * C-reactive protein \<15 mg/l (\< 5 mg/l: normal; \>= 5 mg/l \< 10 mg/l: +; \>=10mg/l \< 100 mg/l: ++; \>=100 mg/l: +++) * Ability to follow study instructions and likely to complete all required visits * Written informed consent of the patient Exclusion Criteria: * Anemia of non-renal causes * Primary hematologic disorder (e.g. myelodysplastic syndrome, sickle cell anemia, hematological malignancy, hemolytic anemia) * Evidence of severe hepatic dysfunction (ALT and/or AST above 2 x upper limit of normal range; or gamma-GT above 3 x upper limit of normal range) * Clinical evidence of current uncontrolled hyperparathyroidism (serum parathyroid hormone \>1500 pg/mL). * Known history of bone marrow disease * Any red blood cell transfusion(s) during the last 12 weeks before screening or during the screening/baseline period * Insufficient concomitant iron treatment during the last 2 months before Visit -2 * Uncontrolled hypertension, defined as a predialysis diastolic blood pressure measurement \>=110 mmHg during the screening period * Congestive heart failure \[New York Heart Association (NYHA) class III and IV\] * Unstable angina pectoris, active cardiac disease, cardiac infarction during the last six months before screening * History of blood coagulation disease * Thrombocytopenia (platelet count \<100.000/µl) * Leukopenia (white blood cell count \< 2.000/µl) * Overt bleeding (acute or chronic bleeding within 2 months of inclusion) or hemolysis * Evidence of acute infectious disease or serious active inflammatory states within one months before screening (Visit -2) or during the screening/baseline period * Suspicion or known PRCA (pure red cell aplasia) * Previously diagnosed HIV or acute hepatitis infection * Treatment for epilepsy within the past 6 months * Planned surgery during the next 7 months (except vascular access surgery) * Any androgen therapy within 2 months before visit -2 and during the study * Therapy with immunosuppressants or any drug known to affect the hematocrit within 1 month before Visit -2 and during the study * Clinical evidence of malignant diseases * Pregnancy, breastfeeding women or women not using adequate birth control measures * Known history of severe drug related allergies * Known allergy to one of the ingredients of the test or reference products or hypersensitivity to mammalian-derived products * Simultaneous participation in another clinical study or participation in a study in the month preceding the start of this study or previously randomized in this study * Participation in an erythropoietin study in the 3 months preceding screening (visit -2) * Any other condition which at the investigator´s discretion may put the patient at risk or which may confound the study results